CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 11/03/22

BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2022 financial results o...

BERKELEY HEIGHTS, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, reported today preliminary dose escalation data from its...

-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma- -Monday, October 31 st @ 10 am ET- BERKELEY HEIGHTS, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cyc...

BERKELEY HEIGHTS, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced it will present preliminary dose esc...

BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in...

If you’re trying to make sense of the stock market today, you’re not alone. July Fed meeting minutes came out. Though they echoed a somewhat dovish tone, investors took caution as the first move with the S&P, Dow, and Nasdaq all retreating from their recent highs. With mor...

Cyclacel Pharmaceuticals ( NASDAQ: CYCC ) stock rose ~16% on Aug. 11 after the company's Q2 net loss narrowed year over year. Net loss was -$4.58M, compared to -$5.13M in Q2 2021. Q2 total other income grew to ~$0.23M, compared to $9K in the prior year p...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch! We’ve got earnings reports, a merger, a stock offeri...

Cyclacel Pharmaceuticals press release ( NASDAQ: CYCC ): Q2 GAAP EPS of -$0.46 beats by $0.08 . Revenue of $0M. As of June 30, 2022, cash and cash equivalents totaled $29.1 million, compared to $36.6 million as of December 31, 2021. For further details see: ...

- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for CDK2 and CDK9 – - Company to host R&D day in ...